Overall rank by patents
#3,253
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Deutsches Krebsforschungszentrum
USPTO PatentsView assignee record - 115 granted patents across 29 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
115
Total patents granted
29
CPC technology areas
14.2
Avg claims per patent
-11%
5-year filing velocity
The verdict
Deutsches holds 115 US patents across 29 technology areas, rank #3,253 of 50,000 tracked assignees.
- #3,253
- of 50,000 US assignees by volume
- Top 15%
- by Innovation Score (49.4/100)
- 14.2
- avg claims per patent
- -11%
- filing velocity, last 5 yrs
Portfolio overview
Deutsches Krebsforschungszentrum has been granted 115 US utility patents between 2015 and 2025, placing Deutsches Krebsforschungszentrum at rank #3,253 across all assignees tracked by PlainPatent. This portfolio spans 29 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.2 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Deutsches Krebsforschungszentrum is one of the more focused assignees in the PatentsView dataset. By volume, Deutsches sits between Cognitive Scale, Inc. (115 patents, rank #3,249) and Institut Curie (115 patents, rank #3,257) - the closest US assignees by grant volume. The composite Innovation Score of 49.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 54 grants, compared with 61 in the 2015–2019 window, a -11% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Deutsches Krebsforschungszentrum's 14.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 29 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Deutsches Krebsforschungszentrum against peers pursuing similar technology classes.
Who files at Deutsches's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cognitive Scale
Cognitive Scale, Inc.
115 patents
- Coherent Logix In…
Coherent Logix, Incorporated
115 patents
- Coinbase
Coinbase, Inc.
115 patents
- Desktop Metal
Desktop Metal, Inc.
115 patents
- Dresser
Dresser, LLC
115 patents
- Hisamitsu Pharmac…
HISAMITSU PHARMACEUTICAL CO., INC.
115 patents
- Hunter Engineering
Hunter Engineering Company
115 patents
- Institut Curie
INSTITUT CURIE
115 patents
- Deutsches Krebsfo… ◀
Deutsches Krebsforschungszentrum
115 patents
What this shows Deutsches holds 115 patents at rank #3,253, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Deutsches
By rank, the assignees closest to #3,253 in granted patent volume.
- Cognitive Scale, Inc. #3,249 · 115 patents
- Coherent Logix, Incorporated #3,250 · 115 patents
- Coinbase, Inc. #3,251 · 115 patents
- Desktop Metal, Inc. #3,252 · 115 patents
- Dresser, Llc #3,254 · 115 patents
- Hisamitsu Pharmaceutical Co., Inc. #3,255 · 115 patents
- Hunter Engineering Company #3,256 · 115 patents
- Institut Curie #3,257 · 115 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Deutsches's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Deutsches's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
49 Top 15% higher than 85% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 9 | 7.8% |
| 2016 | 14 | 12.2% |
| 2017 | 14 | 12.2% |
| 2018 | 9 | 7.8% |
| 2019 | 15 | 13.0% |
| 2020 | 11 | 9.6% |
| 2021 | 10 | 8.7% |
| 2022 | 10 | 8.7% |
| 2023 | 11 | 9.6% |
| 2024 | 8 | 7.0% |
| 2025 | 4 | 3.5% |
Which technologies does Deutsches Krebsforschungszentrum patent most?
Top 15 of 29 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Deutsches Krebsforschungszentrum hold?
Deutsches Krebsforschungszentrum holds 115 US granted patents filed between 2015 and 2025, spanning 29 technology areas.
What is Deutsches Krebsforschungszentrum's Innovation Score?
Deutsches Krebsforschungszentrum has an Innovation Score of 49.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Deutsches Krebsforschungszentrum focus on?
Deutsches Krebsforschungszentrum's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 64 patents. The company has filed patents in 29 CPC subclasses total.
Is Deutsches Krebsforschungszentrum's patent filing rate increasing or decreasing?
Deutsches Krebsforschungszentrum's recent filing velocity is -11% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Deutsches Krebsforschungszentrum's patents?
Deutsches Krebsforschungszentrum's patents average 14.2 claims each. This falls within the standard range, providing solid legal coverage.
How is the Deutsches Krebsforschungszentrum patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Deutsches's 115 grants land it in the top 15% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Deutsches ranks #3,253 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.